Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.

ABSTRACT:

Background

Peanut allergy is common, life-threatening, and without therapeutic options. We evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanut for peanut allergy treatment.

Objective

We sought to evaluate the clinical, safety, and immunologic effects of EPIT for the treatment of peanut allergy.

Methods

In this multicenter, double-blind, randomized, placebo-controlled study, 74 participants with peanut allergy (ages 4-25 years) were treated with placebo (n = 25), Viaskin Peanut 100 μg (VP100; n = 24) or Viaskin Peanut 250 μg (VP250; n = 25; DBV Technologies, Montrouge, France). The primary outcome was treatment success after 52 weeks, which was defined as passing a 5044-mg protein oral food challenge or achieving a 10-fold or greater increase in

SUBMITTER: Jones SM 

PROVIDER: S-EPMC8609774 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature